Tylophorine Analogs as Antitumor Agents

Abstract

Compounds of Formula I are described: preferably subject to the proviso that either (a) R.sup.2 and R.sup.3 together form --O--CH(R.sup.10)--O--, or (b) R.sup.5 and R.sup.6 together form --O--CH(R.sup.10)--O--, wherein R.sup.10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.

abstract = "Compounds of Formula I are described: preferably subject to the proviso that either (a) R.sup.2 and R.sup.3 together form --O--CH(R.sup.10)--O--, or (b) R.sup.5 and R.sup.6 together form --O--CH(R.sup.10)--O--, wherein R.sup.10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.",

N2 - Compounds of Formula I are described: preferably subject to the proviso that either (a) R.sup.2 and R.sup.3 together form --O--CH(R.sup.10)--O--, or (b) R.sup.5 and R.sup.6 together form --O--CH(R.sup.10)--O--, wherein R.sup.10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.

AB - Compounds of Formula I are described: preferably subject to the proviso that either (a) R.sup.2 and R.sup.3 together form --O--CH(R.sup.10)--O--, or (b) R.sup.5 and R.sup.6 together form --O--CH(R.sup.10)--O--, wherein R.sup.10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.